Leidos Holdings, Inc. (LDOS) - Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 27, 2024. Leidos is a Fortune 500 innovation company providing technology solutions in national security and health sectors. Effective fiscal 2024, the company realigned its reporting structure into four segments: National Security & Digital, Health & Civil, Commercial & International, and Defense Systems. Approximately 87% of revenue is derived from U.S. government contracts.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenues | $4,190M | $3,921M | $12,297M | $11,458M |
| Operating Income | $516M | ($336M) | $1,406M | $260M |
| Net Income (Attributable to Leidos) | $364M | ($399M) | $970M | ($30M) |
| Diluted EPS | $2.68 | ($2.91) | $7.13 | ($0.22) |
| Operating Margin | 12.3% | (8.6%) | 11.4% | 2.3% |
| Cash from Operations (9M) | $1,093M (vs. $861M prior year) | |||
| Total Debt | $4.67B (Current: $592M; Long-term: $4.08B) | |||
| Cash & Equivalents | $1,185M | |||
| Backlog (Total) | $40.6B (Funded: $9.1B; Unfunded: $31.5B) |
Material Changes vs. Prior Period
- Profitability Surge: Operating income improved from a loss of $336M in Q3 2023 to $516M in Q3 2024. This year-over-year comparison is significantly impacted by a $599M goodwill impairment charge recorded in the Commercial & International segment in the prior year.
- Revenue Growth: Total revenue increased 6.9% in Q3 and 7.3% YTD. The Health & Civil segment drove significant growth with a 16.1% revenue increase in Q3, attributed to higher volumes and case complexity in managed health services.
- Segment Performance:
- Health & Civil: Operating income rose 73.9% QoQ to $287M.
- Commercial & International: Returned to profitability ($41M operating income) compared to a $646M loss in the prior year, excluding the prior year's impairment.
- Defense Systems: Revenue grew 13.0% to $522M.
- Capital Allocation: The company repurchased $200M of stock in Q3 2024 (totaling $450M YTD) and paid $51M in dividends for the quarter.
Outlook, Risks, and Contingencies
- Government Funding: A continuing resolution passed on September 26, 2024, funds the government through December 20, 2024. A failure to pass appropriations by this date could result in a shutdown, impacting operations.
- Legal Proceedings:
- FCPA Investigation: An ongoing internal investigation regarding international operations has been self-reported to the DOJ and SEC. A Federal Grand Jury Subpoena was received in September 2022. The company cannot estimate potential fines or penalties.
- Antitrust Investigation: The DOJ Antitrust Division issued a subpoena in August 2022 regarding three U.S. Government procurements. The company is cooperating.
- Contract Estimates: Unfavorable changes in contract estimates impacted income by $107M YTD 2024, including $41M in write-downs on UK programs due to cost increases and schedule delays.
- Backlog: Total backlog increased to $40.6B. Net bookings were $8.1B in Q3 and $15.8B YTD.
Investor Verification Checklist
- Impairment Impact: Verify the extent to which Q3 2023 results were distorted by the $599M goodwill impairment to accurately assess organic growth trends.
- UK Program Exposure: Review the specific details of the $41M write-down in UK operations and the potential for further cost/schedule rebaselining.
- Legal Exposure: Monitor updates on the FCPA and Antitrust investigations for potential material financial penalties or reputational damage.
- Government Shutdown Risk: Assess the potential impact of a federal government shutdown after December 20, 2024, given the 87% reliance on U.S. government revenue.
- Debt Covenants: Confirm continued compliance with the 3.75x debt-to-EBITDA covenant, especially given the significant stock repurchase activity.